Back to School: How biopharma can reboot drug development. Access exclusive analysis here
NKTR was up $1.96 (17%) to $13.44 on 3.6 million shares on Monday after Pfizer (PFE) and Aventis (AVE) reported
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury